Shree Ganesh Rem

Shree Ganesh Remedies reported Q2 FY26 revenue of ₹30.32 crores, marking a 23% sequential increase over Q1 FY26, driven by higher volumes and execution. However, year-on-year revenue declined by 6% due to subdued domestic realization and softer European demand. EBITDA for Q2 stood at ₹9.62 crores, with a margin of 31.7%, reflecting a 32% sequential improvement. Net profit for the quarter was ₹4.93 crores, improving 43% sequentially but declining 23% year-on-year, impacted by market softness and increased fixed costs. For H1 FY26, revenue was ₹54.98 crores (down 4% YoY), EBITDA ₹16.92 crores (30.8% margin, down 13% YoY), and net profit ₹8.37 crores (down 24% YoY).

The company is advancing its capacity expansion projects, with the new pilot facility expected to be operational in Q4 FY26. Block 8, recently commissioned, is showing strong capacity utilization trends and is projected to reach 50-60% utilization by year-end. Block 7 remains on track for commercial production in H2 FY27. The planned Dahej expansion, intended for bulkier, high-volume products, has been postponed and is now anticipated two years down the line, to be developed in collaboration with an end customer.

Shree Ganesh Remedies has secured client approvals in Europe for an agrochemical project and initiated engagement with a major European pharmaceutical company. The agrochemical product is slated for commercial launch in 2027, with bulk purchasing commencing then and peak volumes expected in 2029-2030. The specialty chemicals initiative for the Japanese market is progressing positively, with final client approval anticipated by mid-2026, reinforcing the company's strategy to create platforms for future scale-up.

FY26 is identified as a year of consolidation and capability building, focusing on laying a robust foundation for sustainable growth. Management emphasized the inherent lumpiness of results due to long lead-times, project-based investments, and evolving client demands in the sector. Despite this, the company remains confident in its medium to long-term trajectory for healthy growth and meaningful value creation, leveraging capital investments in complex, value-added chemistries.

The company's product portfolio is 60% pharma, primarily serving export markets in Europe, Asia (including Japan), and the US with advanced intermediates. The remaining 40% is in specialty chemicals, catering to agrochemicals, polymer, electronics, and semiconductor industries. Historically, therapeutic categories included anti-psychotic, anti-depression, and hypertension, but recent molecules are more focused on anti-diabetic and oncology. All current intermediates are for generic players, with a strategic shift towards innovator-based products.

The European market continues to experience a slowdown, attributed to European API suppliers reducing stock, a decline in older generic APIs, and a shift by European companies towards more advanced intermediates. The company anticipates competition from China for new generation specialty chemicals, though not fierce. For generic molecules and API intermediates, competition is also expected from local Indian manufacturers, as European buyers increasingly source from India.

The company's robust margins, even in generics, are attributed to its innovation process and chemistry expertise. They pursue backward integration, manufacturing from the cheapest raw materials and extending up to six steps backward. This strategy, combined with continuous improvement in chemistries, processes, and efficiency, allows them to achieve and maintain robust margins. The company does not hold patents but relies on trade secrets for its processes, planning to file patents in developing countries like Europe, US, and Japan in the future.